Geneva, Switzerland - Addex Therapeutics, a biopharmaceutical company listed on SIX and Nasdaq as ADXN, specializing in developing small molecule allosteric modulators for neurological disorders, disclosed it will release its Q1 2026 Financial Results on June 25, 2026. The CEO, Tim Dyer, and the Head of Translational Science, Mikhail Kalinichev, are set to hold a teleconference and webcast for investors, analysts, and media at 16:00 CEST on June 25, 2026, discussing business updates and the Addex product pipeline. This will be available at 15:00 BST, 10:00 EDT, and 07:00 PDT on the same day.